Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Receivables (2020 - 2025)

Caribou Biosciences has reported Receivables over the past 6 years, most recently at $2.0 million for Q4 2025.

  • Quarterly Receivables rose 38.65% to $2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Dec 2025, up 38.65% year-over-year, with the annual reading at $2.0 million for FY2025, 38.65% up from the prior year.
  • Receivables was $2.0 million for Q4 2025 at Caribou Biosciences, up from $1.1 million in the prior quarter.
  • Over five years, Receivables peaked at $6.6 million in Q4 2021 and troughed at $832000.0 in Q2 2021.
  • The 5-year median for Receivables is $2.4 million (2023), against an average of $2.8 million.
  • Year-over-year, Receivables skyrocketed 348.99% in 2021 and then crashed 63.1% in 2022.
  • A 5-year view of Receivables shows it stood at $6.6 million in 2021, then crashed by 63.1% to $2.4 million in 2022, then decreased by 0.61% to $2.4 million in 2023, then tumbled by 41.54% to $1.4 million in 2024, then surged by 38.65% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Receivables are $2.0 million (Q4 2025), $1.1 million (Q3 2025), and $2.0 million (Q2 2025).